36912-00-2 Usage
Uses
Used in Pharmaceutical Industry:
(3aS)-1,2,3,3aβ,5aβ,7,10b,10cβ-Octahydro-3a,10bα-dimethyl-7β-isopropyl-4H,9H-furo[2',3',4':4,5]naphtho[2,1-c]pyran-4,9-dione is used as a potential therapeutic agent for various diseases due to its inhibitory activity against activator protein 1 (AP-1). This activity suggests that it may have applications in treating conditions related to cell proliferation and differentiation, such as cancer.
Used in Research Applications:
In the field of research, (3aS)-1,2,3,3aβ,5aβ,7,10b,10cβ-Octahydro-3a,10bα-dimethyl-7β-isopropyl-4H,9H-furo[2',3',4':4,5]naphtho[2,1-c]pyran-4,9-dione can be used as a tool compound to study the role of activator protein 1 (AP-1) in cellular processes. This may lead to a better understanding of the underlying mechanisms of various diseases and the development of new therapeutic strategies.
Used in Drug Discovery:
The inhibitory activity of (3aS)-1,2,3,3aβ,5aβ,7,10b,10cβ-Octahydro-3a,10bα-dimethyl-7β-isopropyl-4H,9H-furo[2',3',4':4,5]naphtho[2,1-c]pyran-4,9-dione against activator protein 1 (AP-1) makes it a valuable compound in drug discovery efforts. It can be used as a starting point for the development of new drugs targeting AP-1, which may have potential applications in treating a range of diseases, including cancer and other conditions related to cell proliferation and differentiation.
Check Digit Verification of cas no
The CAS Registry Mumber 36912-00-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,9,1 and 2 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 36912-00:
(7*3)+(6*6)+(5*9)+(4*1)+(3*2)+(2*0)+(1*0)=112
112 % 10 = 2
So 36912-00-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H24O4/c1-10(2)15-11-8-13-16-18(3,12(11)9-14(20)23-15)6-5-7-19(16,4)17(21)22-13/h8-10,13,15-16H,5-7H2,1-4H3/t13-,15-,16-,18-,19+/m1/s1
36912-00-2Relevant academic research and scientific papers
Burke, Steven D.,Kort, Michael E.,Strickland, Sharon M.S.,Organ, Helen M.,Silks III, Louis A.
, p. 1503 - 1506 (1994)
An enantioselective total synthesis of nagilactone F is described. Functionalized tricyclic intermediate 3 was prepared using a high-yielding acetal-initiated/vinylsilane-terminated polyene cyclization of 5. Intramolecular alkoxy radical-mediated remote f
Total synthesis of oidiodendrolides and related norditerpene dilactones from a common precursor: Metabolites CJ-14,445, LL-Z1271γ, oidiolactones A, B, C, and D, and nagilactone F
Hanessian, Stephen,Boyer, Nicolas,Reddy, Gone Jayapal,Deschenes-Simard, Benoit
supporting information; experimental part, p. 4640 - 4643 (2009/12/09)
An efficient, high-yielding strategy has been developed for the asymmetric total synthesis of seven norditerpenoid dilactones known for their diverse biological properties. The three key steps employed to obtain a tricyclic lactone intermediate involved a
Enantiospecific syntheses of the potent bioactives nagilactone F and the mould metabolite LL-Z1271α an evaluation of their allelopathic potential
Barrero, Alejandro F.,Sanchez, Juan F.,Elmerabet, Jamal,Jimenez-Gonzalez, David,Macias, Francisco A.,Simonet, Ana M.
, p. 7289 - 7304 (2007/10/03)
Improved syntheses are described for nagilactone F and the antibiotic LL-Z1271α, two of the most potent bioactive members of the podolactone family. The allelopathic potential of some members of this podolactone series has been evaluated, with the result
